Literature DB >> 4364175

Trial of the antiviral action of isoprinosine against rhinovirus infection of volunteers.

A J Soto, T S Hall, S E Reed.   

Abstract

Isoprinosine (NPT-10381) was given orally to a group of 22 volunteers at a daily dose of 6 g for 7 days; a control group of 23 volunteers received placebo. Volunteers were inoculated intranasally with both rhinovirus type 9 and rhinovirus type 31, and the clinical picture, extent of virus shedding, and serological responses were assessed. There was no evidence that the compound had useful antiviral activity under the conditions of this trial.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4364175      PMCID: PMC444410          DOI: 10.1128/AAC.3.3.332

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  THE USE OF VOLUNTEERS.

Authors:  D A TYRRELL
Journal:  Am Rev Respir Dis       Date:  1963-09

2.  Some improved techniques for the study of rhinoviruses using HeLa cells.

Authors:  E J Stott; D A Tyrrell
Journal:  Arch Gesamte Virusforsch       Date:  1968

3.  Effect of isoprinosine against influenza and some other viruses causing respiratory diseases.

Authors:  R L Muldoon; L Mezny; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

  3 in total
  4 in total

1.  Evaluation of isoprinosine in experimental human rhinovirus infection.

Authors:  D M Pachuta; Y Togo; R B Hornick; A R Schwartz; S Tominaga
Journal:  Antimicrob Agents Chemother       Date:  1974-04       Impact factor: 5.191

Review 2.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

3.  Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases.

Authors:  T Nakamura; N Miyasaka; R M Pope; N Talal; I J Russell
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

4.  In vitro antiviral activity and preliminary clinical trials of a new adamantane compound.

Authors:  A Mathur; A S Beare; S E Reed
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.